25 May 2013
Keywords: Novo Nordisk, Hemophilia A, Turoctocog alfa, EMA, FDA, Regulatory filings
Article | 17 October 2012
Denmark’s Novo Nordisk (NOV: N), the world’s largest insulin maker, has submitted regulatory application for turoctocog ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
17 October 2012
24 May 2013
© 2013 thepharmaletter.com